Coherus BioSciences - CHRS Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHRS shares.
View CHRS analyst ratings or view top-rated stocks.

5 analysts have issued 12 month target prices for Coherus BioSciences' shares. Their CHRS share price forecasts range from $11.00 to $26.00. On average, they predict the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 156.6% from the stock's current price.
View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts.

Coherus BioSciences' stock was trading at $7.92 at the start of the year. Since then, CHRS shares have decreased by 18.8% and is now trading at $6.43.
View the best growth stocks for 2023 here.

Coherus BioSciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 12,050,000 shares, an increase of 22.5% from the February 28th total of 9,840,000 shares. Based on an average daily volume of 1,260,000 shares, the short-interest ratio is presently 9.6 days.
View Coherus BioSciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our CHRS earnings forecast.

Coherus BioSciences, Inc. (NASDAQ:CHRS) released its earnings results on Monday, March, 6th. The biotechnology company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.12. The biotechnology company had revenue of $45.35 million for the quarter, compared to the consensus estimate of $45.72 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 422.10% and a negative net margin of 138.24%. During the same period in the prior year, the company earned ($0.60) EPS.

ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust Innovation Leaders ETF (ILDR), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Strategas Global Policy Opportunities ETF (SAGP) and Syntax Stratified SmallCap ETF (SSLY).

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Coherus BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (7.99%), Aristotle Capital Boston LLC (2.68%), Geode Capital Management LLC (1.62%), Peregrine Capital Management LLC (1.44%), Citigroup Inc. (0.99%) and Morgan Stanley (0.92%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends.

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHRS stock can currently be purchased for approximately $6.43.

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $511.89 million and generates $211.04 million in revenue each year. The biotechnology company earns $-291,750,000.00 in net income (profit) each year or ($3.76) on an earnings per share basis.

The company employs 332 workers across the globe.

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.